Pathologic complete response (pCR) after NST is a factor predicting good prognosis, which has been recognized as a surrogate marker for improved disease-free and overall survival.[3–6] However, the ability to achieve pCR in patients with luminal type breast cancer is significantly lower than that in other types, such as triple-negative breast cancer (TNBC) and HER2 type breast cancer.[7–10]. The gene discussed is ERBB2; the disease is breast cancer.